Companies we’ve backed: myTomorrows

Taking a revolutionary approach to fighting diseases

myTomorrows is set to revolutionise an industry valued at an estimated $500 billion worldwide, by giving patients early access to potentially life-saving treatments.

Improving access to drugs in development

Developing drugs to fight diseases is a slow and complex process. MyTomorrows assists with regulatory hurdles to streamline patients getting pre-approval access, and identifies emerging treatments using the latest technology.

This company example is for illustrative purposes only. It should not be considered as an investment recommendation. Any personal opinions mentioned may change and should not be seen as advice or a recommendation.

Investors can access the opportunity to invest in companies like Quit Genius through some of our tax products such as Octopus Titan VCT or the Octopus Ventures EIS Service.

Remember, investing involves risk

Please remember that the value of an investment in VCT or EIS shares, and any income from it, can fall as well as rise. Investors may not get back the full amount they invest.

In relation to tax products, tax treatment depends on individual circumstances and may change in the future. Tax reliefs depend on the VCT maintaining its qualifying status or the portfolio companies maintaining their EIS-qualifying status.

The shares of the smaller companies or VCT shares we invest in could fall or rise in value more than shares listed on the main market of the London Stock Exchange. They may also be harder to sell.

More information and key documents can be viewed on the Octopus Ventures EIS Service and Octopus Titan VCT product pages.

Remember, investing involves risk

We’re here to support you

If you’ve got a question about any of our products or services, please get in touch.

Contact our team

Got a question?
Call us at 0800 316 2067